체외 대장암 스크리닝 검사 시장 보고서 : 제품 유형, 영상 유형, 최종사용자, 지역별(2025-2033년)

The global in-vitro colorectal cancer screening tests market size reached USD 1,049.2 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,658.7 Million by 2033, exhibiting a growth rate (CAGR) of 4.96% during 2025-2033.

In-vitro colorectal cancer screening tests are diagnostic procedures performed to detect adenomas, polyps and symptoms of colorectal cancer. Colorectal cancer refers to a medical condition that is characterized by the abnormal growth of cells in the large intestine, colon and rectum. Fecal occult blood (FOB), lateral flow immuno, transferrin assays, methylated gene, biomarker and guaiac FOB stool test are some of the commonly performed screening tests. In-vitro colorectal cancer screening tests involve the use of cameras that capture images of the digestive tract and transfers them to the recorder tied to the waist of the patient. They are minimally invasive and can aid in timely detection of cancer. As a result, in-vitro colorectal cancer screening tests are widely performed across clinics, hospitals and diagnostics laboratories.

In-Vitro Colorectal Cancer Screening Tests Market Trends:

The increasing prevalence of colorectal cancer among the masses is one of the key factors driving the growth of the market. Moreover, rising awareness regarding the benefits of early detection and timely treatment of cancer is positively impacting the market growth. Various technological advancements, such as the integration of genetic testing in cancer screening tests, are providing a thrust to the market growth. These tests aid in early detection, developing treatment plans, preventing the spread of cancerous cells and minimizing the risks of developing associated disorders. In line with this, the increasing preference for minimally invasive (MI) diagnostic procedures to detect colorectal cancer is favoring the market growth. Other factors, including rising geriatric populations, which is more susceptible to such ailments and significant improvements in the healthcare industry, along with the implementation of various government initiatives mandating cancer screening tests, are anticipated to drive the market toward growth.

Key Market Segmentation:

Breakup by Product:

• Fecal Occult Blood Tests
• Guaiac FOB Stool Test
• Immuno-FOB Agglutination Test
• Lateral Flow Immuno-FOB Test
• Immuno-FOB ELISA Test
• Biomarker Tests
• Tumor M2-PK Stool Test
• Transferrin Assays
• CRC DNA Screening Tests
• Methylated Gene Testing
• Panel DNA Tests

Breakup by Imaging Type:

• Colonoscopy
• Proctoscopy
• CT Scan
• Ultrasound
• MRI
• PET Scan

Breakup by End User:

• Hospitals
• Clinics
• Diagnostic Laboratories
• Others

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Beckman Coulter Inc. (Danaher Corporation), Eiken Chemical Co. Ltd., Epigenomics AG, Exact Sciences Corporation, Hemosure Inc., Immunostics Inc. (Boditech Med Inc.), Medline Industries LP, Merck KGaA, Qiagen N.V., Quest Diagnostics Incorporated, R-Biopharm AG, Siemens AG and Sysmex Corporation.

Key Questions Answered in This Report

• 1.What was the size of the global in-vitro colorectal cancer screening tests market in 2024?
• 2.What is the expected growth rate of the global in-vitro colorectal cancer screening tests market during 2025-2033?
• 3.What has been the impact of COVID-19 on the global in-vitro colorectal cancer screening tests market?
• 4.What are the key factors driving the global in-vitro colorectal cancer screening tests market?
• 5.What is the breakup of the global in-vitro colorectal cancer screening tests market based on the product?
• 6.What is the breakup of the global in-vitro colorectal cancer screening tests market based on the imaging type?
• 7.What is the breakup of the global in-vitro colorectal cancer screening tests market based on end user?
• 8.What are the key regions in the global in-vitro colorectal cancer screening tests market?
• 9.Who are the key players/companies in the global in-vitro colorectal cancer screening tests market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global In-vitro Colorectal Cancer Screening Tests Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Fecal Occult Blood Tests
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 Guaiac FOB Stool Test
    • 6.1.2.2 Immuno-FOB Agglutination Test
    • 6.1.2.3 Lateral Flow Immuno-FOB Test
    • 6.1.2.4 Immuno-FOB ELISA Test
  • 6.1.3 Market Forecast
• 6.2 Biomarker Tests
  • 6.2.1 Market Trends
  • 6.2.2 Key Segments
    • 6.2.2.1 Tumor M2-PK Stool Test
    • 6.2.2.2 Transferrin Assays
  • 6.2.3 Market Forecast
• 6.3 CRC DNA Screening Tests
  • 6.3.1 Market Trends
  • 6.3.2 Key Segments
    • 6.3.2.1 Methylated Gene Testing
    • 6.3.2.2 Panel DNA Tests
  • 6.3.3 Market Forecast

7 Market Breakup by Imaging Type

• 7.1 Colonoscopy
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Proctoscopy
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 CT Scan
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Ultrasound
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 MRI
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 PET Scan
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Clinics
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Diagnostic Laboratories
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Others
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Beckman Coulter Inc. (Danaher Corporation)
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 SWOT Analysis
  • 14.3.2 Eiken Chemical Co. Ltd.
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
  • 14.3.3 Epigenomics AG
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Exact Sciences Corporation
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Hemosure Inc.
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
  • 14.3.6 Immunostics Inc. (Boditech Med Inc.)
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
  • 14.3.7 Medline Industries LP
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 SWOT Analysis
  • 14.3.8 Merck KGaA
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Qiagen N.V.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 Quest Diagnostics Incorporated
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis
  • 14.3.11 R-Biopharm AG
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
  • 14.3.12 Siemens AG
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio
    • 14.3.12.3 Financials
    • 14.3.12.4 SWOT Analysis
  • 14.3.13 Sysmex Corporation
    • 14.3.13.1 Company Overview
    • 14.3.13.2 Product Portfolio
    • 14.3.13.3 Financials
    • 14.3.13.4 SWOT Analysis